Active

NOVARTIS PHARMA

Switched

BE0459093476

Rechtspersoon Public limited company 2 establishments

Kouterveldstraat 2, 1831 Machelen (Brab.) Groothandel in farmaceutische en medische artikelen

Active for

29 year, 10 months

Financials

Financial year 2025

Worth noting

  • The team shrank two years in a row.
  • Little cash and receivables against the short-term debts.

Revenue

€ 378.6 million

▲ 6% vs 2024

Profit

Healthy

€ 11.5 million

▼ 14% vs 2024

Debts

Normal

€ 132.9 million

▲ 37% vs 2024

NOVARTIS PHARMA from Machelen (Brab.), company number BE0459093476, closed financial year 2025 with a result of € 11.5 million after tax. For that financial year NOVARTIS PHARMA recorded revenue of € 378.6 million and equity of € 32.1 million. Compared with financial year 2024, the result moved from € 13.4 million to € 11.5 million. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.

What happened at NOVARTIS PHARMA?

What happened at NOVARTIS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • Nicolas ISTAS stepped down as director. NBB
  • Andrea MAJOCCHI stepped down as director. NBB
  • Federico MAMBRETTI stepped down as director. NBB
  • New annual accounts for financial year 2025: profit of € 11.5 million (▼ 14% vs 2024). Source: NBB ↗
  • Nicolas ISTAS became a director. NBB
  • New establishment in Etterbeek. KBO
  • Andrea MAJOCCHI became a director. NBB
  • Federico MAMBRETTI became a director. NBB

In short

From € 3.4 million loss in 2022 to € 11.5 million profit in 2025.

Paid € 15.2 million in corporate taxes since 2022.

Best year ever: 2023, with € 26.1 million profit.

Paid out € 26.5 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at NOVARTIS PHARMA? We notify you, reason included.

Follow NOVARTIS PHARMA

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Novartis Pharma AG 98.3%
Novartis AG 1.7%
NOVARTIS PHARMA

The shares are held by Novartis Pharma AG (98.3%) and Novartis AG (1.7%).

See the full network in the app

Directors

According to the 2025 annual accounts

Nicolas ISTAS

Director

Also active at: Sint Carolus Mayerhof

since 2022 · until 2028

Andrea MAJOCCHI

Director

since 2022 · until 2028

Federico MAMBRETTI

Director

Also active at: sandoz

since 2021 · until 2027

Shareholders

Novartis Pharma AG

98.3%

Novartis AG

1.7%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kouterveldstraat 2

1831 Machelen (Brab.)

2.332.320.755

Belliardstraat 40

1040 Etterbeek

Active since 9 March 2022

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0459.093.476
VAT number
BE 0459.093.476
Registered office
Kouterveldstraat 2, 1831 Machelen (Brab.)
Names & denominations
NOVARTIS PHARMA
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
25 October 1996
Peppol
Active · Active since 6 Mar 2026
Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

Overige gespecialiseerde groothandel in voedingswaren

Groothandel in andere voedingsmiddelen, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

Frequently asked questions

What is the enterprise number of NOVARTIS PHARMA?
The enterprise number of NOVARTIS PHARMA is BE0459093476.
What is the address of NOVARTIS PHARMA?
The registered office of NOVARTIS PHARMA is located at Kouterveldstraat 2, 1831 Machelen (Brab.).
When was NOVARTIS PHARMA founded?
NOVARTIS PHARMA was founded on 25 October 1996.
What is the main activity of NOVARTIS PHARMA?
The main activity of NOVARTIS PHARMA is "Groothandel in farmaceutische en medische artikelen" (NACE code 46460).
Does NOVARTIS PHARMA have a website?
No website is currently known for NOVARTIS PHARMA.
How much profit did NOVARTIS PHARMA make in 2025?
NOVARTIS PHARMA posted a profit after taxes of € 11,516,937 in financial year 2025.
What is the revenue of NOVARTIS PHARMA?
In its most recent annual accounts (2025), NOVARTIS PHARMA reported revenue of € 378,550,712.
How many employees does NOVARTIS PHARMA have?
According to the 2025 annual accounts, NOVARTIS PHARMA has 207.8 full-time equivalents (FTE).
Where can I find the annual accounts of NOVARTIS PHARMA?
NOVARTIS PHARMA files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of NOVARTIS PHARMA?
According to the 2025 annual accounts, the directors of NOVARTIS PHARMA are: Nicolas ISTAS, Andrea MAJOCCHI, Federico MAMBRETTI.
Who owns NOVARTIS PHARMA?
The shares are held by Novartis Pharma AG (98.3%) and Novartis AG (1.7%).
Who are the shareholders of NOVARTIS PHARMA?
According to the 2025 annual accounts, the shareholders of NOVARTIS PHARMA are: Novartis Pharma AG (98.3%), Novartis AG (1.7%).